Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) had its price target lifted by investment analysts at Needham & Company LLC from $8.00 to $9.00 in a research report issued on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s price objective indicates a potential upside of 41.07% from the company’s previous close.
A number of other research analysts have also recently commented on the company. The Goldman Sachs Group upped their target price on Autolus Therapeutics from $3.20 to $4.80 and gave the company a “neutral” rating in a research note on Wednesday, December 13th. Deutsche Bank Aktiengesellschaft assumed coverage on Autolus Therapeutics in a research note on Thursday, November 9th. They issued a “buy” rating and a $10.00 price objective on the stock. Finally, William Blair reissued an “outperform” rating on shares of Autolus Therapeutics in a research note on Wednesday, November 15th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $7.97.
Autolus Therapeutics Stock Performance
Institutional Trading of Autolus Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of AUTL. Two Sigma Advisers LP bought a new stake in Autolus Therapeutics during the 1st quarter valued at $25,000. BNP Paribas Financial Markets boosted its position in Autolus Therapeutics by 337.3% during the 4th quarter. BNP Paribas Financial Markets now owns 4,268 shares of the company’s stock valued at $27,000 after acquiring an additional 3,292 shares in the last quarter. CI Private Wealth LLC bought a new stake in Autolus Therapeutics during the 4th quarter valued at $28,000. Sei Investments Co. bought a new stake in Autolus Therapeutics during the 4th quarter valued at $29,000. Finally, Advisor Group Holdings Inc. boosted its position in Autolus Therapeutics by 3,285.0% during the 4th quarter. Advisor Group Holdings Inc. now owns 16,925 shares of the company’s stock valued at $32,000 after acquiring an additional 16,425 shares in the last quarter. Institutional investors own 64.78% of the company’s stock.
About Autolus Therapeutics
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma.
- Five stocks we like better than Autolus Therapeutics
- How to Invest in EV Charging Stations
- Uber quadruples EPS estimates, but is growth decelerating?
- EV Stocks and How to Profit from Them
- 3 stocks set to benefit from record Valentine’s Day spending
- How to Invest in Toy Stocks
- Tradeweb is a disruptive pure play on financial market liquidity
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.